To investigate the predictive performance of these biomarkers for NAFLD mortality and HCC carcinogenesis, the optimal cutoff for serum sCD163 levels was determined based on ROC curve analysis of all 243 patients with NAFLD (Fig. 3a). Here, CD163 is linked to metabolic dysfunction-associated steatotic liver disease.